دورية أكاديمية
أعرض في EDS

Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review.

التفاصيل البيبلوغرافية
العنوان: Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review.
المؤلفون: van Schoonhoven AV; Unit of PharmacoTherapy, Epidemiology & Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, the Netherlands., Gout-Zwart JJ; Asc Academics, Groningen, the Netherlands.; Department of Nephrology, University of Groningen, University Medical Centre Groningen (UMCG), Groningen, the Netherlands., de Vries MJS; Unit of PharmacoTherapy, Epidemiology & Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, the Netherlands., van Asselt ADI; Department of Epidemiology, University Medical Centre Groningen, Groningen, the Netherlands.; Department of Health Sciences, University of Groningen, University Medical Centre Groningen (UMCG), Groningen, the Netherlands., Dvortsin E; Asc Academics, Groningen, the Netherlands., Vemer P; Unit of PharmacoTherapy, Epidemiology & Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, the Netherlands.; Department of Epidemiology, University Medical Centre Groningen, Groningen, the Netherlands., van Boven JFM; Department of General Practice & Elderly Care, University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands.; Department of Clinical Pharmacy & Pharmacology, University of Groningen, University Medical Centre Groningen (UMCG), Groningen, the Netherlands., Postma MJ; Unit of PharmacoTherapy, Epidemiology & Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, the Netherlands.; Department of Health Sciences, University of Groningen, University Medical Centre Groningen (UMCG), Groningen, the Netherlands.; Department of Economics, Econometrics & Finance, University of Groningen, Faculty of Economics & Business, Groningen, The Netherlands.
المصدر: PloS one [PLoS One] 2019 Sep 06; Vol. 14 (9), pp. e0221856. Date of Electronic Publication: 2019 Sep 06 (Print Publication: 2019).
نوع المنشور: Journal Article; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Costs and Cost Analysis/*statistics & numerical data , Diabetes Mellitus, Type 2/*economics, Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/epidemiology ; Humans ; Netherlands/epidemiology
مستخلص: Background: Type 2 diabetes mellitus (T2DM) is an established risk factor for cardiovascular and nephropathic events. In the Netherlands, prevalence of T2DM is expected to be as high as 8% by 2025. This will result in significant clinical and economic impact, highlighting the need for well-informed reimbursement decisions for new treatments. However, availability and consistent use of costing methodologies is limited.
Objective: We aimed to systematically review recent costing data for T2DM-related cardiovascular and nephropathic events in the Netherlands.
Methods: A systematic literature review in PubMed and Embase was conducted to identify available Dutch cost data for T2DM-related events, published in the last decade. Information extracted included costs, source, study population, and costing perspective. Finally, papers were evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS).
Results: Out of initially 570 papers, 36 agreed with the inclusion criteria. From these studies, 150 cost estimates for T2DM-related clinical events were identified. In total, 29 cost estimates were reported for myocardial infarction (range: €196-€27,038), 61 for stroke (€495-€54,678), fifteen for heart failure (€325-€16,561), 24 for renal failure (€2,438-€91,503), and seventeen for revascularisation (€3,000-€37,071). Only four estimates for transient ischaemic attack were available, ranging from €587 to €2,470. Adherence to CHEERS was generally high.
Conclusions: The most expensive clinical events were related to renal failure, while TIA was the least expensive event. Generally, there was substantial variation in reported cost estimates for T2DM-related events. Costing of clinical events should be improved and preferably standardised, as accurate and consistent results in economic models are desired.
Competing Interests: The funder (Asc Academics) provided support in the form of salaries for authors JJGZ and ED, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
References: N Engl J Med. 1997 Jan 30;336(5):332-6. (PMID: 9011785)
Cost Eff Resour Alloc. 2003 Feb 26;1(1):2. (PMID: 12773219)
J Telemed Telecare. 2013 Jul;19(5):242-8. (PMID: 24163233)
Neth Heart J. 2013 May;21(5):230-5. (PMID: 23456884)
BMC Cardiovasc Disord. 2014 Jun 13;14:77. (PMID: 24927776)
Heart. 2015 Dec;101(24):1980-8. (PMID: 26552756)
J Med Econ. 2016 Aug;19(8):742-9. (PMID: 26985982)
Am Heart J. 2011 Dec;162(6):1096-104. (PMID: 22137084)
Europace. 2018 Jan 1;20(1):12-18. (PMID: 27733465)
Clin Ther. 2010 Jun;32(6):1103-21. (PMID: 20637965)
J Occup Rehabil. 2011 Sep;21(3):325-34. (PMID: 21656250)
Circulation. 2007 May 1;115(17):2299-306. (PMID: 17420341)
Diabetes Ther. 2017 Aug;8(4):753-765. (PMID: 28523483)
Health Econ. 2008 Jan;17(1 Suppl):S33-45. (PMID: 18186036)
Value Health. 2017 Dec;20(10):1260-1269. (PMID: 29241885)
Eur Heart J. 2001 May;22(9):751-61. (PMID: 11350107)
Arch Cardiovasc Dis. 2010 May;103(5):310-6. (PMID: 20619241)
Value Health. 2014 Nov;17(7):A328. (PMID: 27200554)
Cost Eff Resour Alloc. 2010 Nov 17;8:21. (PMID: 21083901)
Value Health. 2008 Mar-Apr;11(2):199-206. (PMID: 18380631)
Am Heart J. 2006 Jan;151(1):206-12. (PMID: 16368320)
Stroke. 1995 Oct;26(10):1830-6. (PMID: 7570734)
Cardiovasc Diabetol. 2016 Mar 22;15:48. (PMID: 27001409)
Open Med. 2009;3(3):e123-30. (PMID: 21603045)
Nephrol Dial Transplant. 2013 Jul;28(7):1865-73. (PMID: 23766337)
Ned Tijdschr Geneeskd. 2000 Oct 7;144(41):1959-64. (PMID: 11048560)
Health Policy. 2000 Apr;51(3):135-47. (PMID: 10720684)
Clin Drug Investig. 2014 Feb;34(2):135-46. (PMID: 24243529)
Radiology. 2004 Oct;233(1):101-12. (PMID: 15333770)
Stroke. 2013 Oct;44(10):2923-5. (PMID: 23943217)
Am Fam Physician. 2012 Sep 15;86(6):521-6. (PMID: 23062043)
Eur J Health Econ. 2009 Feb;10(1):39-45. (PMID: 18340472)
Pharmacoeconomics. 2007;25(9):769-82. (PMID: 17803335)
Eur J Cardiovasc Prev Rehabil. 2008 Apr;15(2):230-3. (PMID: 18391653)
Ned Tijdschr Geneeskd. 2009;153:A580. (PMID: 19785785)
Neth J Med. 2003 Nov;61(11):355-64. (PMID: 14768718)
BMJ. 2011 Mar 30;342:d1672. (PMID: 21450800)
Value Health. 2014 Mar;17(2):223-30. (PMID: 24636380)
Neurology. 2015 Jun 2;84(22):2208-15. (PMID: 25934858)
QJM. 2005 Jun;98(6):415-25. (PMID: 15879443)
Value Health. 2010 Mar-Apr;13(2):230-41. (PMID: 19804435)
Am J Cardiovasc Drugs. 2014 Dec;14(6):451-62. (PMID: 25326294)
Diabet Med. 2002 Mar;19(3):246-53. (PMID: 11918627)
Transplant Proc. 2014 Dec;46(10):3289-96. (PMID: 25498039)
Radiology. 2010 Aug;256(2):585-97. (PMID: 20656842)
Health Policy. 1998 Jun;44(3):215-32. (PMID: 10182294)
PLoS One. 2011;6(10):e26139. (PMID: 22022539)
PLoS One. 2014 Aug 05;9(8):e103974. (PMID: 25093723)
Nephrol Dial Transplant. 2006 Dec;21(12):3514-9. (PMID: 16921189)
Lancet. 1998 Aug 29;352(9129):673-81. (PMID: 9728982)
J Am Soc Nephrol. 2005 Jan;16(1):201-9. (PMID: 15563567)
Eur J Health Econ. 2011 Oct;12(5):479-87. (PMID: 20593297)
Value Health. 2013 Mar-Apr;16(2):231-50. (PMID: 23538175)
BMJ Open. 2015 Nov 27;5(11):e008220. (PMID: 26614618)
Crit Care Med. 2006 Jan;34(1):65-75. (PMID: 16374158)
Int J Technol Assess Health Care. 2006 Fall;22(4):518-24. (PMID: 16984687)
Health Care Manag Sci. 2006 Aug;9(3):287-94. (PMID: 17016935)
Lancet. 2010 Jun 26;375(9733):2215-22. (PMID: 20609967)
Curr Med Res Opin. 2010 Mar;26(3):641-51. (PMID: 20070142)
Int J Cardiol. 2013 Oct 15;168(6):5336-43. (PMID: 23992927)
Health Econ Rev. 2015 Dec;5(1):27. (PMID: 26400849)
Neth Heart J. 2005 Aug;13(7-8):259-268. (PMID: 25696506)
Cerebrovasc Dis. 2013;35(2):113-23. (PMID: 23406838)
Health Policy. 1994 Mar;28(1):37-50. (PMID: 10134586)
Am J Cardiol. 1995 Oct 15;76(11):830-3. (PMID: 7572666)
Value Health. 2014 Nov;17(7):A485. (PMID: 27201429)
Neth Heart J. 2005 Nov;13(11):393-400. (PMID: 25696430)
PLoS One. 2017 Nov 9;12(11):e0187477. (PMID: 29121647)
تواريخ الأحداث: Date Created: 20190907 Date Completed: 20200305 Latest Revision: 20240719
رمز التحديث: 20240719
مُعرف محوري في PubMed: PMC6730996
DOI: 10.1371/journal.pone.0221856
PMID: 31490989
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0221856